Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial) | Synapse
March 3, 2026
Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial)
Key Points
The study examines how different radiation doses impact tumor resection rates in thoracic esophageal squamous cell carcinoma.
Important metrics include the effectiveness of various radiation doses and their influence on surgical outcomes.
This is a randomized study testing neoadjuvant chemoradiotherapy in patients with resectable tumors.
Optimizing radiation doses could improve surgical outcomes, but further research is necessary to confirm findings.